Surgery Partners Financials - Benzinga

Surgery Partners Inc

SGRYNASDAQ

Trade with Public

Trade with Public

$14.40

al cierre: Sep 28, 5:00 PM EST

$14.40

N/A

After hour: Sep 25, 4:00 PM EST

Panorámica general Noticias Previsión de beneficios Eventos Precios objetivoFinanzasSentimiento Propiedad Comparar Opciones Informe de acciones

Surgery Partners Financials

Surgery Partners (SGRY) financial statements — income, revenue, gross margin and key metrics.

Earnings & Guidance News

PRO
Surgery Partners Updates FY2026 Revenue Guidance To $3.08B-$3.18B, Adjusted EBITDA To At Least $489M Following Idaho Falls Sale

Benzinga Newsdesk

PRO
Surgery Partners Q2 Adj. EPS $0.10 Beats $0.06 Estimate, Sales $848.900M Beat $830.366M Estimate

Surgery Partners (NASDAQ:SGRY) reported quarterly earnings of $0.10 per share which beat the analyst consensus estimate of $0.06 by 66.67 percent. This is a 41.18 percent decrease over earnings of $0.17 per share from

Benzinga Newsdesk

PRO
Surgery Partners Affirms FY2026 Sales Guidance of $3.350B-$3.450B vs $3.408B Est

Surgery Partners (NASDAQ:SGRY) affirms FY2026 sales outlook from $3.350 billion-$3.450 billion to $3.350 billion-$3.450 billion vs $3.408 billion estimate.

Benzinga Newsdesk

Surgery Partners Monetizes Idaho Assets As It Chases Faster Growth

Surgery Partners rises after agreeing to sell Idaho Falls hospital stakes for $795 million while reaffirming its 2026 outlook

Vandana Singh

PRO
Surgery Partners Affirms FY2026 Sales Guidance of $3.350B-$3.450B vs $3.408B Est

Surgery Partners (NASDAQ:SGRY) affirms FY2026 sales outlook from $3.350 billion-$3.450 billion to $3.350 billion-$3.450 billion vs $3.408 billion estimate.

Benzinga Newsdesk

PRO
Surgery Partners Affirms FY2026 Sales Guidance of $3.350B-$3.450B vs $3.411B Est

2026 GuidanceFull year 2026 revenue guidance reaffirmed to be in the range of $3.35 billion to $3.45 billion and Adjusted EBITDA of at least $530 million

Benzinga Newsdesk

© 2026 Benzinga | All Rights Reserved